<DOC>
	<DOCNO>NCT01371487</DOCNO>
	<brief_summary>The purpose study evaluate effect high-fat , high calorie meal single dose PK GSK1120212 subject solid tumor .</brief_summary>
	<brief_title>GSK1120212 Food-effect Study</brief_title>
	<detailed_description>open-label , randomize , 2-treatment , 2-period , crossover study incomplete wash-out evaluate effect high-fat , high calorie meal single dose PK GSK1120212 subject solid tumor . Subjects assign fast/fed sequence accord randomization code provide site GSK subject randomize one 2 possible treatment sequence ( Table 1 ) sequence consist 2 treatment : single 2.0 mg dose GSK1120212 administer fasted condition single 2.0 mg dose GSK1120212 administer high-fat , high-calorie meal</detailed_description>
	<mesh_term>Trametinib</mesh_term>
	<criteria>A subject eligible inclusion study follow criterion apply : 1 . Male female ; 18 year age old time consent 2 . Capable give write informed consent , include compliance requirement restriction list consent form . 3 . Able swallow retain oral medication . 4 . Histologically cytologically confirm diagnosis solid tumor . 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 ( Appendix 3 ) . 6 . Adequate baseline organ function define Table 5 Definitions Adequate Baseline Organ Function Absolute neutrophil count great equal 1.2 × 109/L Hemoglobin great equal to9 g/dL Platelets great equal 75 × 109/L Prothrombin time ( PT ) , International normalization ratio ( INR ) Partial thromboplastin time ( PTT ) less equal 1.5 time ULN Hepatic Total bilirubin less equal 1.5 time ULN ALT less equal 2.5 time ULN Renal Creatinine less equal 1.5 time ULN Calculated creatinine clearance great equal 50 mL/min 24hour urine creatinine clearance great equal 50 mL/min Cardiac LVEF great equal LLNc ECHO MUGA 1 . INR great 1.5 time ULN acceptable case subject receive therapeutic anticoagulant warfarin long INR monitor study accord clinical practice . 2 . Calculated CockcroftGault formula ( see Appendix 2 ) . 3 . If LLN define give institution , ejection fraction must great equal 50 % . 7 . Women childbearing potential must negative serum pregnancy test within 14 day first dose study treatment agree use effective contraception , define Section 7.1.1 , study 6 week follow last dose study treatment . 8 . Men female partner childbearing potential must either prior vasectomy agree use effective contraception describe Section 7.1.2 time first dose study treatment 16 week follow last dose study treatment ( base lifecycle sperm ) . A subject eligible inclusion study follow criterion apply : 1 . Currently receive cancer therapy ( e.g. , chemotherapy delay toxicity , extensive radiation therapy , immunotherapy , biologic therapy , major surgery ) within 3 week prior randomization ; chemotherapy regimens without delayed toxicity within 2 week prior randomization ; use investigational anticancer drug within 4 week prior randomization . 2 . Has unresolved Grade 2 great toxicity ( base NCICTCAE , version 4.0 ) [ NCI Common Terminology Criteria Adverse Events , 2009 ] previous anticancer therapy except Grade 2 decrease hemoglobin level alopecia . 3 . Has preexist peripheral neuropathy great equal Grade 2 . 4 . Has participate clinical trial receive investigational product within 30 day , 5 halflives twice duration biological effect investigational product , whichever longer , prior first dose study treatment study . 5 . Has participate study result make donation blood blood product excess 500 mL within 56 day first dose study treatment . 6 . Has presence active GI disease condition ( e.g. , gastrectomy , bariatric surgery , small large bowel resection , cholecystectomy exclude ) may interfere significantly absorption drug . If clarification need whether condition significantly affect absorption drug , contact GSK Medical Monitor . 7 . Has serious and/or unstable preexist medical ( aside malignancy exception ) , psychiatric disorder , condition could interfere subject 's safety , obtain informed consent compliance study procedure , opinion investigator GSK Medical Monitor . 8 . Has history interstitial lung disease pneumonitis . 9 . Is currently use prohibit medication ( ) require use prohibited medication study ( see Section 8.2 ) . • NOTE : Use anticoagulant warfarin permit ; however , INR must monitor accordance local institutional practice . 10 . Has history current evidence/risk RVO CSR : History RVO CSR , predispose factor RVO CSR ( i.e. , uncontrolled glaucoma ocular hypertension , uncontrolled systemic disease hypertension diabetes mellitus , history hyperviscosity hypercoagulability syndrome ) Visible retinal pathology assess ophthalmic exam consider risk factor RVO CSR : Evidence new optic disc cup Intraocular pressure great 21 mmHg measure tonography 11 . Has symptomatic untreated leptomeningeal brain metastasis spinal cord compression Note : Subjects previously treat condition stable central nervous system ( CNS ) disease ( verified consecutive imaging study ) great 3 month , asymptomatic currently take corticosteroid , stable dose corticosteroid least 1 month prior Day 1 study permit . Subjects permit receive enzymeinducing antiepileptic drug ( EIAEDs ) . 12 . Has QtcB QTcF ( prefer ) great equal 480 msec . 13 . Has history evidence cardiovascular risk include follow : 14 . History evidence current clinically significant uncontrolled arrhythmia . Exception : Subjects control atrial fibrillation great 30 day prior randomization eligible . 15 . History acute coronary syndrome ( include myocardial infarction unstable angina ) , coronary angioplasty , stenting within 6 month prior randomization . 16 . History evidence current great equal Class II congestive heart failure define New York Heart Association ( NYHA ) ( Appendix 4 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>